Quest to Offer Cancer Screening Products of TriPath Imaging
By HospiMedica staff writers
Posted on 27 Mar 2003
Under the terms of a recently announced collaboration agreement, Quest Diagnostics, Inc. (Teterboro, NJ, USA) will be offering the 13 Series integrated solution for cervical cancer screening of TriPath Imaging, Inc. (Burlington, NC, USA) in selected locations. Posted on 27 Mar 2003
The 13 Series includes the test pack (SurePath), slide processor (PrepStain), and the slide profiler (FocalPoint). Quest will also evaluate the 13 series relative to its immediate and future needs for cervical cancer screening. In addition, Quest has installed the Tele-pathology system of TriPath in two locations and is evaluating various aspects of the system's utility. TriPath develops and sells products to improve the clinical management of cancer, including detection, diagnosis, staging, and treatment. Quest is the leading provider of diagnostic laboratory testing, information, and services in the United States.
"We believe that our technologies and expanding product pipeline will create significant value for Quest Diagnostics and its customers,” said Paul R. Sohmer, M.D., president, CEO, and chairman of TriPath Imaging.
Related Links:
Quest
TriPath
Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
